<?xml version="1.0"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
<channel>
<title>BloggingStocks</title>
<link>http://www.bloggingstocks.com</link>
<description>BloggingStocks</description>
<image>
<url>http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif</url>
<title>BloggingStocks</title>
<link>http://www.bloggingstocks.com</link>
</image>
<language>en-us</language>
<copyright>Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only.</copyright>
<generator>Blogsmith http://www.blogsmith.com/</generator><item><title><![CDATA[Analyst upgrades: PCOP, ZUMZ, NSC and OCCX]]></title><link>http://www.bloggingstocks.com/2007/10/11/analyst-upgrades-pcop-zumz-nsc-and-occx/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2007/10/11/analyst-upgrades-pcop-zumz-nsc-and-occx/</guid><comments>http://www.bloggingstocks.com/2007/10/11/analyst-upgrades-pcop-zumz-nsc-and-occx/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/analyst-reports/" rel="tag">Analyst Reports</a>, <a href="http://www.bloggingstocks.com/category/analyst-upgrades-and-downgrades/" rel="tag">Analyst Upgrades and Downgrades</a>, <a href="http://www.bloggingstocks.com/category/nsc/" rel="tag">Norfolk Southern Corp. (NSC)</a></p><a href="http://www.theflyonthewall.com/splashPage.php?source=AOL"><img vspace="4" hspace="4" border="1" align="right" alt="" src="http://www.blogcdn.com/www.bloggingstocks.com/media/2007/10/fly-logo-(aol).gif" /></a><strong>MOST NOTEWORTHY:</strong> Pharmacopeia, Zumiez, Norfolk Southern and OccuLogix were today's noteworthy upgrades:<br />
<ul>
    <li>CIBC upgraded <a href="http://finance.aol.com/quotes/pharmacopeia-drug-discovery-inc/pcop/nas">Pharmacopeia</a> (NASDAQ: <a href="http://finance.aol.com/quotes/pharmacopeia-drug-discovery-inc/pcop/nas">PCOP</a>) to Sector Outperformer from Sector Performer, as they believe its lead cardiovascular drug DARA has the potential to become an important new therapy for hypertension and diabetic nephropathy. <br /></li>
    <li>Think Equity upgraded shares of <a href="http://finance.aol.com/quotes/zumiez-inc/zumz/nas">Zumiez</a> (NASDAQ: <a href="http://finance.aol.com/quotes/zumiez-inc/zumz/nas">ZUMZ</a>) to Buy from Accumulate to reflect the company's strong same store sales growth. <br /></li>
    <li><a href="http://finance.aol.com/quotes/norfolk-southern-corporation/nsc/nys">Norfolk Southern Corporation</a> (NYSE: <a href="http://finance.aol.com/quotes/norfolk-southern-corporation/nsc/nys">NSC</a>) was upgraded to Equal Weight from Underweight at Lehman Brothers on valuation. <br /></li>
    <li>Caris upgraded shares of <a href="http://finance.aol.com/quotes/occulogix-inc/occx/nas">OccuLogix</a> (NASDAQ: <a href="http://finance.aol.com/quotes/occulogix-inc/occx/nas">OCCX</a>) to Above Average from Average, as they believe weakness in the stock creates a buying opportunity. The firm believes the stock has dropped due to concerns about the company's cash position, but thinks the current stock price underestimates the revenue potential of the company's assets.</li>
</ul>
<strong>OTHER UPGRADES:</strong><br />
<ul>
    <li><a href="http://finance.aol.com/quotes/bre-properties-incorporated/bre/nys">BRE Properties</a> (NYSE: <a href="http://finance.aol.com/quotes/bre-properties-incorporated/bre/nys">BRE</a>) was upgraded to Outperform from Neutral at Credit Suisse. <br /></li>
    <li>Bear Stearns raised <a href="http://finance.aol.com/quotes/capital-product-partners-l-p-common-units-representing-limited-partner-interests/cplp/nas">Capital Product Partners</a> (NASDAQ: <a href="http://finance.aol.com/quotes/capital-product-partners-l-p-common-units-representing-limited-partner-interests/cplp/nas">CPLP</a>) to Outperform from Peer Perform. <br /></li>
    <li>JP Morgan upgraded <a href="http://finance.aol.com/quotes/celestica-sub-vtg/cls/nys">Celestica</a> (NYSE: <a href="http://finance.aol.com/quotes/celestica-sub-vtg/cls/nys">CLS</a>) to Neutral from Underweight. <br /></li>
    <li>Stifel upgraded <a href="http://finance.aol.com/quotes/sl-green-realty-corp/slg/nys">SL Green Realty</a> (NYSE: <a href="http://finance.aol.com/quotes/sl-green-realty-corp/slg/nys">SLG</a>) to Buy from Hold.</li>
</ul><p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2007/10/11/analyst-upgrades-pcop-zumz-nsc-and-occx/">Analyst upgrades: PCOP, ZUMZ, NSC and OCCX</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Thu, 11 Oct 2007 11:00:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2007/10/11/analyst-upgrades-pcop-zumz-nsc-and-occx/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/1010781/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2007/10/11/analyst-upgrades-pcop-zumz-nsc-and-occx/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>analyst</category><category>bre</category><category>bre properties</category><category>BreProperties</category><category>capital product partners</category><category>CapitalProductPartners</category><category>celestica</category><category>cls</category><category>cplp</category><category>norfolk southern</category><category>NorfolkSouthern</category><category>nsc</category><category>occulogix</category><category>occx</category><category>pcop</category><category>pharmacopeia</category><category>sl green realty</category><category>slg</category><category>SlGreenRealty</category><category>upgrade</category><category>zumiez</category><category>zumz</category><dc:creator><![CDATA[Eric Buscemi]]></dc:creator><pubDate>Thu, 11 Oct 2007 11:00:00 EST</pubDate></item><item><title><![CDATA[Analyst initiations 9-6-07: MSFT, CRM, TLEO and MFE]]></title><link>http://www.bloggingstocks.com/2007/09/06/analyst-initiations-9-6-07-msft-crm-tleo-and-mfe/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2007/09/06/analyst-initiations-9-6-07-msft-crm-tleo-and-mfe/</guid><comments>http://www.bloggingstocks.com/2007/09/06/analyst-initiations-9-6-07-msft-crm-tleo-and-mfe/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/analyst-reports/" rel="tag">Analyst Reports</a>, <a href="http://www.bloggingstocks.com/category/msft/" rel="tag">Microsoft (MSFT)</a>, <a href="http://www.bloggingstocks.com/category/analyst-initiations/" rel="tag">Analyst Initiations</a>, <a href="http://www.bloggingstocks.com/category/crm/" rel="tag">salesforce.com inc (CRM)</a>, <a href="http://www.bloggingstocks.com/category/zolt/" rel="tag">Zoltek Co (ZOLT)</a></p><strong><a href="http://www.theflyonthewall.com/splashPage.php?source=AOL"><img vspace="4" hspace="4" border="1" align="right" alt="" src="http://www.blogcdn.com/www.bloggingstocks.com/media/2007/09/fly-logo-(aol).gif" /></a>MOST NOTEWORTHY:</strong> European pharmaceuticals, Microsoft, Salesforce.com, Taleo and McAfee were today's noteworthy initiations:<br />
<ul>
    <li>UBS resumed coverage of <a href="http://finance.aol.com/quotes/novartis-ag-ads/nvs/nys">Novartis AG</a> (NYSE: <a href="http://finance.aol.com/quotes/novartis-ag-ads/nvs/nys">NVS</a>) with a Buy rating and <a href="http://finance.aol.com/quotes/astrazeneca-plc-ads/azn/nys">AstraZeneca</a> (NYSE: <a href="http://finance.aol.com/quotes/astrazeneca-plc-ads/azn/nys">AZN</a>), <a href="http://finance.aol.com/quotes/roche-holding-ltd-adr/rhhby/nao">Roche Holding</a> (OTC: <a href="http://finance.aol.com/quotes/roche-holding-ltd-adr/rhhby/nao">RHHBY</a>), <a href="http://finance.aol.com/quotes/sanofi-aventis-sa/sny/nys">Sanofi-Aventis</a> (NYSE: <a href="http://finance.aol.com/quotes/sanofi-aventis-sa/sny/nys">SNY</a>) and <a href="http://finance.aol.com/quotes/glaxo-smith-kline-plc/gsk/nys">GlaxoSmithKline</a> (NYSE: <a href="http://finance.aol.com/quotes/glaxo-smith-kline-plc/gsk/nys">GSK</a>) with Neutral ratings. <br /></li>
    <li>Deutsche Bank believes new product leverage can bring upside to consensus operating margin expectations at <a href="http://finance.aol.com/quotes/microsoft-corporation/msft/nas">Microsoft Corporation</a> (NASDAQ: <a href="http://finance.aol.com/quotes/microsoft-corporation/msft/nas">MSFT</a>) and they view shares as attractively valued given its growth profile. The firm started shares with a Buy rating and $33 target.</li>
    <li>Keybanc initiated shares of <a href="http://finance.aol.com/quotes/salesforce-com-inc/crm/nys">Salesforce.com</a> (NYSE: <a href="http://finance.aol.com/quotes/salesforce-com-inc/crm/nys">CRM</a>) with a Hold rating and sees slowing growth rates for revenue and net subscriber additions throughout the remainder of FY08 and beyond and thinks investor expectations are too high.</li>
    <li>Keybanc also started shares of <a href="http://finance.aol.com/quotes/taleo-corporation-cl-a/tleo/nas">Taleo Corporation</a> (NASDAQ: <a href="http://finance.aol.com/quotes/taleo-corporation-cl-a/tleo/nas">TLEO</a>) with a Buy rating and $27 target, as it is well-positioned to gain market share in the Human Capital Management space.</li>
    <li>Thomas Weisel believes <a href="http://finance.aol.com/quotes/mcafee-incorporated/mfe/nys">McAfee Inc</a> (NYSE: <a href="http://finance.aol.com/quotes/mcafee-incorporated/mfe/nys">MFE</a>) will benefit from PC market growth, enhanced awareness of the company's brand, and its renewed focus on product development for the midmarket corporate segment, and started shares with a Market Weight rating and $37 target.</li>
</ul>
<strong>OTHER INITIATIONS:</strong><br />
<ul>
    <li> <a href="http://finance.aol.com/quotes/lululemon-athletica-inc/lulu/nas">Lululemon Athletica</a> (NASDAQ: <a href="http://finance.aol.com/quotes/lululemon-athletica-inc/lulu/nas">LULU</a>) was started at William Blair with an Outperform rating and at UBS with a Neutral rating and $37 target.</li>
    <li>Merrill Lynch initiated shares of <a href="http://finance.aol.com/quotes/zoltek-companies-inc/zolt/nas">Zoltek Companies Inc</a> (NASDAQ: <a href="http://finance.aol.com/quotes/zoltek-companies-inc/zolt/nas">ZOLT</a>) with a Buy rating and $50 target.</li>
    <li>Bear Stearns started shares of <a href="http://finance.aol.com/quotes/capital-product-partners-l-p-common-units-representing-limited-partner-interests/cplp/nas">Capital Product Partners</a> (NASDAQ: <a href="http://finance.aol.com/quotes/capital-product-partners-l-p-common-units-representing-limited-partner-interests/cplp/nas">CPLP</a>) with a Peer Perform rating.</li>
    <li>Oppenheimer initiated shares of <a href="http://finance.aol.com/quotes/bfc-financial-corporation/bff/nys">BFC Financial</a> (NYSE: <a href="http://finance.aol.com/quotes/bfc-financial-corporation/bff/nys">BFF</a>) with a Buy rating and $3.50 target.</li>
</ul><p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2007/09/06/analyst-initiations-9-6-07-msft-crm-tleo-and-mfe/">Analyst initiations 9-6-07: MSFT, CRM, TLEO and MFE</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Thu, 06 Sep 2007 11:13:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2007/09/06/analyst-initiations-9-6-07-msft-crm-tleo-and-mfe/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/982481/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2007/09/06/analyst-initiations-9-6-07-msft-crm-tleo-and-mfe/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>analyst</category><category>astrazeneca</category><category>azn</category><category>bfc financial</category><category>BfcFinancial</category><category>bff</category><category>capital product partners</category><category>CapitalProductPartners</category><category>cplp</category><category>crm</category><category>firm</category><category>glaxosmithkline</category><category>gsk</category><category>initiation</category><category>lulu</category><category>lululemon</category><category>mcafee</category><category>mfe</category><category>microsoft</category><category>msft</category><category>novartis</category><category>nvs</category><category>rhhby</category><category>roche holding</category><category>RocheHolding</category><category>salesforce.com</category><category>sanofi-aventis</category><category>sny</category><category>taleo</category><category>tleo</category><category>zolt</category><category>zoltek</category><dc:creator><![CDATA[Eric Buscemi]]></dc:creator><pubDate>Thu, 06 Sep 2007 11:13:00 EST</pubDate></item></channel></rss>
